Insulin therapy in young children

Abstract

The management of type 1 diabetes mellitus (T1D) in early childhood is conditioned by physiological and behavioral particularities that demand specific insulinization regimens. The early onset of the disease is associated with an increase in morbidity and mortality and the development of micro- and macrovascular complications, which places the highest priority on achieving metabolic targets early to mitigate long-term risks.

During this period, the developing central nervous system exhibits high susceptibility; chronic hyperglycemia, severe hypoglycemic episodes, and glycemic instability are directly linked to alterations in brain structure and function. From a therapeutic perspective, insulin dosing in young children requires precision due to low body mass and extremely low basal and prandial requirements. Traditional administration tools often present limitations for dosing the small required fractions. Added to this are age-related behavioral determinants, such as irregular food intake and picky eating, factors that complicate preprandial insulin calculation and necessitate adjustments based on actual intake. The unpredictability of energy expenditure from spontaneous physical activity and the frequency of intercurrent infectious processes increase the instability of glycemic control, complicating daily management for caregivers.

Faced with this variability, treatment intensification through medical technology offers effective solutions. Continuous glucose monitoring (CGM) identifies trends and provides preventive alerts for hypoglycemic events. Continuous subcutaneous insulin infusion allows adapting the insulin dose to the specific requirements of the young child. Integrated and automated insulin delivery systems have been shown to safely optimize metabolic control parameters in this population. However, current registries indicate that a significant percentage of children still do not achieve recommended HbA1c targets, highlighting barriers in daily adaptation.

In conclusion, insulin therapy in preschool-aged children demands continuous assessment of requirements, structured diabetes education for the family, and the gradual integration of monitoring and automated insulin delivery systems adapted to the needs of this vital stage, thus ensuring proper physical and neurocognitive development.